

## SAFETY DATA SHEET

**CLYNAV Injection** 

## SECTION 1: Identification of the substance/mixture and of the company/ undertaking

1.1 Product identifier

: CLYNAV Injection **Product name** : 12400000192 **Product code Product description** : Not available.

AV6770; CLYNAV injeksjonsvæske, oppløsning til atlantisk laks; CLYNAV solution Other means of

for injection for Atlantic salmon identification

1.2 Relevant identified uses of the substance or mixture and uses advised against

: Veterinary vaccine. **Identified uses** Uses advised against None known.

1.3 Details of the supplier of the safety data sheet

Elanco Ireland Limited

Fitzwilliam Hall. Fitzwilliam Place Dublin 2, Ireland, D02 T292

e-mail address of person responsible for this SDS

: elanco sds@elancoah.com

1.4 Emergency telephone number

**Supplier or Manufacturer** 

**Supplier Emergency** : CHEMTREC International: 00 1 703-527-3887 (24 hours)

telephone number CHEMTREC: +353 1 901 4670 (Local)

#### SECTION 2: Hazards identification

#### 2.1 Classification of the substance or mixture

**Product definition** : Mixture

Classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Not classified.

The product is not classified as hazardous according to Regulation (EC) 1272/2008 as amended.

See Section 11 for more detailed information on health effects and symptoms.

2.2 Label elements

elements

Signal word : No signal word.

**Hazard statements** : No known significant effects or critical hazards.

**Precautionary statements** 

**Prevention** : Not applicable. Response : Not applicable. : Not applicable. **Storage** : Not applicable. **Disposal** Supplemental label : Not applicable.

Product name: **CLYNAV Injection** IE: ENGLISH 1/10 Date of previous issue : No previous validation

Version: 0.01 Date of revision: 22 February 2024

#### SECTION 2: Hazards identification

**Annex XVII - Restrictions** on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles

: Not applicable.

#### Special packaging requirements

Containers to be fitted with child-resistant

: Not applicable.

fastenings

**Tactile warning of danger** : Not applicable.

#### 2.3 Other hazards

Product meets the criteria for PBT or vPvB according to Regulation (EC) No. 1907/2006, Annex XIII

: This mixture does not contain any substances that are assessed to be a PBT or a

vPvB.

Other hazards which do

: None known.

### not result in classification

### SECTION 3: Composition/information on ingredients

3.2 Mixtures : Mixture

There are no ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment, are PBTs, vPvBs or Substances of equivalent concern, or have been assigned a workplace exposure limit and hence require reporting in this section.

#### **SECTION 4: First aid measures**

#### 4.1 Description of first aid measures

Eye contact : Immediately flush eyes with plenty of water, occasionally lifting the upper and lower

eyelids. Check for and remove any contact lenses. Get medical attention if irritation

occurs.

Inhalation : Remove victim to fresh air and keep at rest in a position comfortable for breathing.

Get medical attention if symptoms occur.

Skin contact : Flush contaminated skin with plenty of water. Remove contaminated clothing and

shoes. Get medical attention if symptoms occur.

: Wash out mouth with water. If material has been swallowed and the exposed Ingestion

> person is conscious, give small quantities of water to drink. Do not induce vomiting unless directed to do so by medical personnel. Get medical attention if symptoms

**Protection of first-aiders** : No action shall be taken involving any personal risk or without suitable training.

#### 4.2 Most important symptoms and effects, both acute and delayed

#### Over-exposure signs/symptoms

**Eye contact** : No specific data. Inhalation : No specific data. Skin contact : No specific data. Ingestion : No specific data.

#### 4.3 Indication of any immediate medical attention and special treatment needed

Notes to physician : Treat symptomatically. Contact poison treatment specialist immediately if large

quantities have been ingested or inhaled.

Specific treatments : No specific treatment.

Product name : **CLYNAV Injection** IE: ENGLISH Version: 0.01 2/10 Date of previous issue : No previous validation

Date of revision: 22 February 2024

### SECTION 5: Firefighting measures

#### 5.1 Extinguishing media

Suitable extinguishing media

: Use an extinguishing agent suitable for the surrounding fire.

**Unsuitable extinguishing** media

: None known.

Hazards from the substance or mixture : In a fire or if heated, a pressure increase will occur and the container may burst.

**Hazardous combustion** products

: No specific data.

#### 5.3 Advice for firefighters

Special protective actions for fire-fighters

: Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.

**Special protective** equipment for fire-fighters : Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode. Clothing for fire-fighters (including helmets, protective boots and gloves) conforming to European standard EN 469 will provide a basic level of protection for chemical incidents.

### SECTION 6: Accidental release measures

5.2 Special hazards arising from the substance or mixture

### 6.1 Personal precautions, protective equipment and emergency procedures

For non-emergency personnel

: No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilt material. Put on appropriate personal protective equipment.

For emergency responders

: If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".

#### 6.2 Environmental precautions

: Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).

#### 6.3 Methods and material for containment and cleaning up

**Small spill** 

: Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.

#### Large spill

Stop leak if without risk. Move containers from spill area. Prevent entry into sewers, water courses, basements or confined areas. Wash spillages into an effluent treatment plant or proceed as follows. Contain and collect spillage with noncombustible, absorbent material e.g. sand, earth, vermiculite or diatomaceous earth and place in container for disposal according to local regulations. Dispose of via a licensed waste disposal contractor.

#### 6.4 Reference to other sections

: See Section 1 for emergency contact information. See Section 8 for information on appropriate personal protective equipment. See Section 13 for additional waste treatment information.

Product name: **CLYNAV Injection** IE: ENGLISH 3/10 Date of previous issue : No previous validation

Version: 0.01 Date of revision: 22 February 2024

### **SECTION 7: Handling and storage**

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

#### 7.1 Precautions for safe handling

**Protective measures** 

Advice on general occupational hygiene

- : Put on appropriate personal protective equipment (see Section 8).
- Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

#### 7.2 Conditions for safe storage, including any incompatibilities

Store between the following temperatures: 2 to 8°C (35.6 to 46.4°F). Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

#### 7.3 Specific end use(s)

Recommendations : Not available.

Industrial sector specific : Not available.

solutions

### **SECTION 8: Exposure controls/personal protection**

The information in this section contains generic advice and guidance. Information is provided based on typical anticipated uses of the product. Additional measures might be required for bulk handling or other uses that could significantly increase worker exposure or environmental releases.

#### 8.1 Control parameters

#### Occupational exposure limits

Product/ingredient name	Exposure limit values
No exposure limit value known.	

#### **Biological exposure indices**

No exposure indices known.

# Recommended monitoring procedures

: Reference should be made to monitoring standards, such as the following: European Standard EN 689 (Workplace atmospheres - Guidance for the assessment of exposure by inhalation to chemical agents for comparison with limit values and measurement strategy) European Standard EN 14042 (Workplace atmospheres - Guide for the application and use of procedures for the assessment of exposure to chemical and biological agents) European Standard EN 482 (Workplace atmospheres - General requirements for the performance of procedures for the measurement of chemical agents) Reference to national guidance documents for methods for the determination of hazardous substances will also be required.

#### **DNELs/DMELs**

No DNELs/DMELs available.

#### **PNECs**

No PNECs available

#### 8.2 Exposure controls

Appropriate engineering controls

: Good general ventilation should be sufficient to control worker exposure to airborne contaminants.

**Individual protection measures** 

Product name : CLYNAV Injection IE : ENGLISH

Version :0.01 Date of revision :22 February 2024

4/10

### **SECTION 8: Exposure controls/personal protection**

#### **Hygiene measures**

: Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.

#### **Eye/face protection**

Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: safety glasses with side-shields.

#### Skin protection

**Hand protection** 

: Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary.

#### **Body protection**

: Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

Other skin protection

: Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

**Respiratory protection** 

Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.

## **Environmental exposure** controls

Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

### SECTION 9: Physical and chemical properties

The conditions of measurement of all properties are at standard temperature and pressure unless otherwise indicated.

#### 9.1 Information on basic physical and chemical properties

#### **Appearance**

Physical state : Liquid.

Colour : Not available.

Odour : Not available.

Odour threshold : Not available.

Melting point/freezing point : Not available.

Initial boiling point and : Not available.

boiling range

Flammability : Not available.

Lower and upper explosion : Not available.

limit

Flash point : Not available.

Auto-ignition temperature : Not available.

Decomposition temperature : Not available.

pH : Not available.

Viscosity : Not available.

Solubility(ies) : Not available.

Solubility in water : Not available.

Partition coefficient: n-octanol/ : Not applicable.

water

Vapour pressure :

Product name :CLYNAV InjectionIE : ENGLISHVersion : 0.01Date of revision : 22 February 2024Date of previous issue : No previous validation5/10

### **SECTION 9: Physical and chemical properties**

	Vapour Pressure at 20°C			Vapour pressure at 50°C		
Ingredient name	mm Hg	kPa	Method	mm Hg	kPa	Method
water	17.5	2.3				

Evaporation rate : Not available.

Relative density : Not available.

Vapour density : Not available.

Explosive properties : Not available.

Oxidising properties : Not available.

**Particle characteristics** 

Median particle size : Not applicable.

### SECTION 10: Stability and reactivity

**10.1 Reactivity** : No specific test data related to reactivity available for this product or its ingredients.

**10.2 Chemical stability** : The product is stable.

10.3 Possibility of hazardous reactions

: Under normal conditions of storage and use, hazardous reactions will not occur.

10.4 Conditions to avoid : No specific data.

10.5 Incompatible materials : No specific data.

10.6 Hazardous decomposition products

: Under normal conditions of storage and use, hazardous decomposition products

should not be produced.

## **SECTION 11: Toxicological information**

#### 11.1 Information on toxicological effects

**Acute toxicity** 

**Conclusion/Summary**: Not available.

**Acute toxicity estimates** 

N/A

**Irritation/Corrosion** 

Conclusion/Summary : Not available.

**Sensitisation** 

**Conclusion/Summary**: Not available.

**Mutagenicity** 

**Conclusion/Summary**: Not available.

**Carcinogenicity** 

**Conclusion/Summary**: Not available.

Reproductive toxicity

**Conclusion/Summary**: Not available.

**Teratogenicity** 

Conclusion/Summary: Not available.

Specific target organ toxicity (single exposure)

Not available.

Specific target organ toxicity (repeated exposure)

Not available.

Product name : CLYNAV Injection IE : ENGLISH

Version :0.01 Date of revision :22 February 2024 Date

### **SECTION 11: Toxicological information**

#### **Aspiration hazard**

Not available.

Information on likely routes

of exposure

: Not available.

### Potential acute health effects

Eye contact
 Inhalation
 No known significant effects or critical hazards.
 Skin contact
 No known significant effects or critical hazards.
 Ingestion
 No known significant effects or critical hazards.

#### Symptoms related to the physical, chemical and toxicological characteristics

Eye contact : No specific data.

Inhalation : No specific data.

Skin contact : No specific data.

Ingestion : No specific data.

#### Delayed and immediate effects as well as chronic effects from short and long-term exposure

**Short term exposure** 

Potential immediate : Not available.

effects

Potential delayed effects : Not available.

Long term exposure

Potential immediate

: Not available.

effects

Potential delayed effects : Not available.

Potential chronic health effects

Not available.

**Conclusion/Summary**: Not available.

General : No known significant effects or critical hazards.
 Carcinogenicity : No known significant effects or critical hazards.
 Mutagenicity : No known significant effects or critical hazards.
 Reproductive toxicity : No known significant effects or critical hazards.

#### 11.2 Information on other hazards

#### 11.2.1 Endocrine disrupting properties

Not available.

11.2.2 Other information

Not available.

### **SECTION 12: Ecological information**

12.1 Toxicity

**Conclusion/Summary**: Not available.

12.2 Persistence and degradability

**Conclusion/Summary**: Not available.

12.3 Bioaccumulative potential

Not available.

12.4 Mobility in soil

Soil/water partition : Not available.

coefficient (Koc)

Mobility : Not available.

Product name: CLYNAV Injection IE: ENGLISH

Date of previous issue : No previous validation

7/10

Version :0.01 Date of revision :22 February 2024

### **SECTION 12: Ecological information**

#### 12.5 Results of PBT and vPvB assessment

This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

#### 12.6 Endocrine disrupting properties

Not available.

#### 12.7 Other adverse effects

No known significant effects or critical hazards.

### **SECTION 13: Disposal considerations**

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

#### 13.1 Waste treatment methods

#### **Product**

**Methods of disposal** 

The generation of waste should be avoided or minimised wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction.

**Hazardous waste** 

: Within the present knowledge of the supplier, this product is not regarded as hazardous waste, as defined by EU Directive 2008/98/EC.

### **Packaging**

**Methods of disposal** 

: The generation of waste should be avoided or minimised wherever possible. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible.

**Special precautions** 

This material and its container must be disposed of in a safe way. Empty containers or liners may retain some product residues. Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers.

## **SECTION 14: Transport information**

	ADR/RID	ADN	IMDG	IATA
14.1 UN number or ID number	Not regulated.	Not regulated.	Not regulated.	Not regulated.
14.2 UN proper shipping name	-	-	-	-
14.3 Transport hazard class(es)	-	-	-	-
14.4 Packing group	-	-	-	-
14.5 Environmental hazards	No.	No.	No.	No.

user

14.6 Special precautions for : Transport within user's premises: always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.

14.7 Maritime transport in bulk according to IMO instruments

: Not available.

Product name: **CLYNAV Injection** IE: ENGLISH 8/10

Version: 0.01 Date of revision: 22 February 2024

### **SECTION 15: Regulatory information**

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

EU Regulation (EC) No. 1907/2006 (REACH)

Annex XIV - List of substances subject to authorisation

**Annex XIV** 

None of the components are listed.

Substances of very high concern

None of the components are listed.

Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles

No listed substance

**Other EU regulations** 

Industrial emissions : Not listed

(integrated pollution prevention and control) -

Air

Industrial emissions : Not listed

(integrated pollution prevention and control) -

Water

Explosive precursors : Not applicable.

Ozone depleting substances (1005/2009/EU)

Not listed.

Prior Informed Consent (PIC) (649/2012/EU)

Not listed.

**Persistent Organic Pollutants** 

Not listed.

**Seveso Directive** 

This product is not controlled under the Seveso Directive.

15.2 Chemical safety assessment

This product contains substances for which Chemical Safety Assessments are still required.

#### SECTION 16: Other information

Indicates information that has changed from previously issued version.

Abbreviations and

: ATE = Acute Toxicity Estimate

acronyms

CLP = Classification, Labelling and Packaging Regulation [Regulation (EC) No.

1272/2008]

DMEL = Derived Minimal Effect Level
DNEL = Derived No Effect Level

EUH statement = CLP-specific Hazard statement

N/A = Not available

PBT = Persistent, Bioaccumulative and Toxic PNEC = Predicted No Effect Concentration RRN = REACH Registration Number

SGG = Segregation Group

vPvB = Very Persistent and Very Bioaccumulative

#### Procedure used to derive the classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Classification	Justification		
Not classified.			

#### Full text of abbreviated H statements

Not applicable.

#### Full text of classifications [CLP/GHS]

Product name: CLYNAV Injection IE: ENGLISH

9/10

### **SECTION 16: Other information**

Not applicable.

Date of issue/ Date of

revision

: 2/22/2024

Date of previous issue : No previous validation

Version : 0.01

#### **Notice to reader**

As of the date of issuance, we are providing available information relevant to the handling of this material in the workplace. All information contained herein is offered with the good faith belief that it is accurate. THIS SAFETY DATA SHEET SHALL NOT BE DEEMED TO CREATE ANY WARRANTY OF ANY KIND (INCLUDING WARRANTY OF MERCHANT ABILITY OR FITNESS FOR A PARTICULAR PURPOSE). In the event of an adverse incident associated with this material, this safety data sheet is not intended to be a substitute for consultation with appropriately trained personnel. Nor is this safety data sheet intended to be a substitute for product literature which may accompany the finished product.

For additional information contact: Elanco Animal Health

0011+1-877-352-6261 0011+1-800-428-4441

Product name :CLYNAV InjectionIE : ENGLISHVersion : 0.01Date of revision : 22 February 2024Date of previous issue : No previous validation10/10